. /.   WORLD TRADE  
ORGANIZATION  IP/N/10/CAN/1 
8 October 2007 
 (07-4285) 
Council for Trade-Related Aspects  
of Intellectual Property Rights Original:   English/ 
 French 
 
 
 
NOTIFICATION UNDER PARAGRAPH 2(C) OF THE DECISION OF 30 AUGUST 2003 
ON THE IMPLEMENTATION OF PARAG RAPH 6 OF THE DOHA DECLARATION 
ON THE TRIPS AGREEMENT AND PUBLIC HEALTH 
 
CANADA 
   The following notification has been received fro m the delegation of Canada on 4 October 2007 
for circulation to the Council for TRIPS. 
 
______________ 
 
 
 In accordance with paragraph 2(c) of the WT O General Council Decisi on of 30 August 2003 
on the Implementation of Paragraph 6 of the Doha  Declaration on the TRIPS Agreement and Public 
Health, attached
* 1 is the authorization granted on 19 September 2007 by Canada's Commissioner of 
Patents to Apotex, Inc, pursuant to section 21.04 of the Patent Act.2  Rwanda had previously filed 
a related notification, dated 17 July 2007, pursuant to paragraph 2(a) of the same Decision of the 
WTO General Council (IP/N/9/RWA/1).  
 Pursuant to paragraph 2(c) and 2(b)( iii) of the Decision of 30 August 2003 on the 
Implementation of paragraph 6 of the Doha Declaration on the TRI PS Agreement and Public Health, 
the information on the shipment (quantities and distinguishing features) will be posted on the 
licensee’s website at:  www.apotex.com/apotriavir/abouttriavir.asp.  
                                                     
 
* In English only. 
 
1 Canada’s Commissioner of Patents authorization can also be found at: 
http://strategis.gc.ca/sc_mrksv/cipo/new/CAMR_Authorization.pdf. 
2 The WTO General Council Decision was implemented in Canada by an Act to amend the Patent Act 
and the Food and Drugs Act (The Jean Chrétien Pledge to Africa Act) , of 2004. The text of Canada’s Patent Act 
may be found at http://laws.justice.gc.ca/en/showdoc /cs/P-4/bo-ga:s_21_01//en#anchorbo-ga:s_21_01.  
 IP/N/10/CAN/1 
Page 2  
 
  ANNEX 
 
 
AUTHORIZATION UNDER SECTION 21.04 OF THE PATENT ACT 
 
 In the matter of application for authorizati on number CAMR-1 by Apotex, Inc. for export to 
Rwanda of the following pharmaceutical product:  (a) if the pharmaceutical product is a drug as set out in section 2 of the Food and Drugs Act :  A 
fixed dose combination tablet of lamivudine (150mg ) + nevirapine (200mg) + zidovudine (300mg), as 
provided in Schedule 1 to the Patent Act 
 (b) if the pharmaceutical product is a medical device:   
1. I hereby authorize Apotex, Inc. whose postal address is  
   150 Signet Drive   Toronto, Ontario   M9L 1T9  
 to make, construct and use, the patented inve ntions identified in patent numbers 2,311,988;  
2,070,230;  2,068,790;  2,286,126;  2,216,634;  2,105,487;  2,059,263;  2,009,637 and 2,030,056 
solely for purposes directly related to the ma nufacture of the above-mentioned pharmaceutical 
product, and to sell it for export to the above-mentioned country or WTO Member.  
2. The quantity of the pharmaceutical product authorized to be manufactured by this 
authorization is 15,600,000 tablets.  3. In accordance with section 21.09 of the Act, th is authorization is valid for a period of two 
years, beginning on the date shown below.  
 
Granted at Gatineau, Quebec, the 19
th day of September, 2007-10-05 
 Mary Carman Commissioner of Patents 
 
__________